Backbone Degradable Polymer-drug Conjugates for the Treatment of Ovarian Cancer
用于治疗卵巢癌的主链可降解聚合物-药物缀合物
基本信息
- 批准号:8921139
- 负责人:
- 金额:$ 49.24万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-09-26 至 2017-02-28
- 项目状态:已结题
- 来源:
- 关键词:AcuteAdverse effectsAnimal ModelAntimitotic AgentsAntineoplastic AgentsAwardBiocompatibleBiodistributionCancer ModelCell divisionClinicClinical TrialsCollaborationsCombined Modality TherapyCytidineDNADataDevelopmentDoseDose-LimitingDrug CarriersDrug CombinationsDrug Delivery SystemsEvaluationFDA approvedGenerationsGoalsHealthInvestigational DrugsLaboratoriesLegal patentMalignant neoplasm of ovaryMaximum Tolerated DoseMicrotubulesMolecular WeightMusOligopeptidesOrganOvarian CarcinomaPaclitaxelPermeabilityPharmaceutical PreparationsPhasePolymersPublicationsRegimenResearchResource AllocationSideSiteSmall Business Technology Transfer ResearchStagingSystemTherapeuticTimeTimeLineToxic effectTranslationsTreatment EfficacyTreatment ProtocolsTreatment outcomeUnited States National Institutes of HealthVertebral columnX-Ray Computed Tomographybasebiodegradable polymercancer therapychemical synthesischemotherapycopolymerdesigngemcitabinein vivoinnovationmethacrylamidenovelnucleoside analogovarian neoplasmpreclinical studyprotein aminoacid sequencescale upsingle photon emission computed tomographysuccesstripolyphosphatetumor
项目摘要
DESCRIPTION (provided by applicant): The purpose of this Phase II STTR project is to develop a polymeric system for the combination delivery of two antineoplastic agents, gemcitabine and paclitaxel. Based on the successful results of the STTR Phase I award, this Phase II proposal details the rationale and research plan for the synthesis and evaluation of in vivo efficacy of two novel macromolecular therapeutics with diverse and complementary mode of action for the treatment of ovarian carcinoma. Their design is based on new, innovative long-circulating backbone degradable N-(2- hydroxypropyl)methacrylamide (HPMA) copolymer - drug conjugates. The polymeric carrier will be composed of alternating HPMA copolymer segments (blocks) and enzymatically degradable oligopeptide sequences. Each construct will contain multiple copies of either gemcitabine or paclitaxel. The drugs are attached to the backbone via a lysosomally degradable spacer that will allow intracellular release and bioactivity. The choice of drugs bodes well for the success of the project. Gemcitabine is a synthetic nucleoside analog of cytidine. Its triphosphate metabolite is incorporated into DNA, thereby stopping cell division. Gemcitabine has demonstrated activity in several ovarian cancer models and has been approved by FDA for combination therapy of ovarian cancer. Paclitaxel is a mitotic inhibitor, which acts by stabilizing microtubules, thereby inhibiting their breakdown during cellular division It is currently indicated as first-line and subsequent therapy for the treatment of advanced stages of ovarian cancer. The long circulating time of the new, innovative backbone degradable carriers will result in augmented tumor accumulation due to the EPR (enhanced permeability and retention) effect. In addition, the combination of two polymer-drug conjugates with diverse mechanisms of action will result in enhanced efficacy of ovarian cancer treatment and minimal adverse effects. The specific aims of the proposal are three-fold: a) To scale up of the synthesis and to characterize backbone degradable HPMA copolymer-drug (gemcitabine and paclitaxel) conjugates containing enzymatically degradable sequences in the backbone and in side chains; b) To establish the maximum tolerated dose (MTD) as well as the acute toxicity of the conjugates and their combination in vivo; and c) To evaluate the biodistribution, clearance, anticancer efficacy and dose escalation studies of the conjugates in vivo. The ultimate goal of this project is to develop an effective and marketable drug combination with a novel drug delivery system for the treatment of ovarian cancer where the drugs are localized at the site of the tumor, adverse effects of chemotherapy are minimized and efficacy maximized.
描述(由申请人提供):这个第二阶段STTR项目的目的是开发一种聚合物系统,用于两种抗肿瘤药物吉西他滨和紫杉醇的联合给药。基于STTR第一阶段奖的成功结果,这项第二阶段的建议详细说明了合成和评估两种具有不同和互补作用模式的新型高分子治疗卵巢癌药物的原理和研究计划。他们的设计基于创新的长循环主干可降解N-(2-羟丙基)甲基丙烯酰胺(HPMA)共聚物-药物结合物。聚合物载体将由交替的HPMA共聚链段(块)和可酶降解的寡肽序列组成。每个结构将包含吉西他滨或紫杉醇的多个副本。这些药物通过溶酶体可降解的间隔物连接到骨架上,这种间隔物将允许细胞内释放和生物活性。药物的选择对该项目的成功是个好兆头。吉西他滨是一种人工合成的胞苷类似物。它的三磷酸代谢物被结合到DNA中,从而阻止细胞分裂。吉西他滨已在几种卵巢癌模型中显示出活性,并已被FDA批准用于卵巢癌的联合治疗。紫杉醇是一种有丝分裂抑制剂,其作用是稳定微管,从而抑制其在细胞分裂过程中的分解。目前,紫杉醇被认为是治疗晚期卵巢癌的一线和后续疗法。由于EPR(增强型渗透性和滞留)效应,新型可降解骨架载体的长循环时间将导致肿瘤堆积增加。此外,两种具有不同作用机制的聚合物-药物结合物的结合将导致卵巢癌治疗的疗效增强和不良反应最小。该提案的具体目标有三个方面:a)扩大合成规模,并表征骨架可降解的HPMA共聚物-药物(吉西他滨和紫杉醇)结合物,这些结合物在主链和侧链中包含可酶降解的序列;b)确定结合物及其组合的最大耐受量(MTD)以及在体内的急性毒性;以及c)评估结合物在体内的生物分布、清除、抗癌效果和剂量递增研究。这个项目的最终目标是开发一种有效的、有市场价值的药物组合和一种新型的药物输送系统来治疗卵巢癌,其中药物定位于肿瘤部位,最大限度地减少化疗的不良反应,并使疗效最大化。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JINDRICH H. KOPECEK其他文献
JINDRICH H. KOPECEK的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JINDRICH H. KOPECEK', 18)}}的其他基金
Coiled-coil Based Drug-Free Macromolecular Therapeutics
基于卷曲线圈的无药大分子治疗
- 批准号:
8291234 - 财政年份:2011
- 资助金额:
$ 49.24万 - 项目类别:
Coiled-coil Based Drug-Free Macromolecular Therapeutics
基于卷曲线圈的无药大分子治疗
- 批准号:
8645644 - 财政年份:2011
- 资助金额:
$ 49.24万 - 项目类别:
Coiled-coil Based Drug-Free Macromolecular Therapeutics
基于卷曲线圈的无药大分子治疗
- 批准号:
8457100 - 财政年份:2011
- 资助金额:
$ 49.24万 - 项目类别:
Coiled-coil Based Drug-Free Macromolecular Therapeutics
基于卷曲线圈的无药大分子治疗
- 批准号:
8021749 - 财政年份:2011
- 资助金额:
$ 49.24万 - 项目类别:
Backbone Degradable Polymer-drug Conjugates for the Treatment of Ovarian Cancer
用于治疗卵巢癌的主链可降解聚合物-药物缀合物
- 批准号:
8779604 - 财政年份:2011
- 资助金额:
$ 49.24万 - 项目类别:
DOUBLE-TARGETED MACROMOLECULAR THERAPEUTICS FOR THE TREATMENT OF PROSTATE CANCER
治疗前列腺癌的双靶点大分子疗法
- 批准号:
7759540 - 财政年份:2008
- 资助金额:
$ 49.24万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 49.24万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 49.24万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 49.24万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 49.24万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 49.24万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 49.24万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 49.24万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 49.24万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 49.24万 - 项目类别:
Downsides of downhill: The adverse effects of head vibration associated with downhill mountain biking on visuomotor and cognitive function
速降的缺点:与速降山地自行车相关的头部振动对视觉运动和认知功能的不利影响
- 批准号:
2706416 - 财政年份:2022
- 资助金额:
$ 49.24万 - 项目类别:
Studentship














{{item.name}}会员




